Disrupting Insulin and IGF Receptor Function in Cancer
Open Access
- 8 January 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (2) , 555
Abstract
The insulin and insulin-like growth factor (IGF) system plays an important role in regulating normal cell proliferation and survival. However, the IGF system is also implicated in many malignancies, including breast cancer. Preclinical studies indicate several IGF blocking approaches, such as monoclonal antibodies and tyrosine kinase inhibitors, have promising therapeutic potential for treating diseases. Uniformly, phase III clinical trials have not shown the benefit of blocking IGF signaling compared to standard of care arms. Clinical and laboratory data argue that targeting Type I IGF receptor (IGF1R) alone may be insufficient to disrupt this pathway as the insulin receptor (IR) may also be a relevant cancer target. Here, we review the well-studied role of the IGF system in regulating malignancies, the limitations on the current strategies of blocking the IGF system in cancer, and the potential future directions for targeting the IGF system.Keywords
Funding Information
- National Institutes of Health (R01CA237000, P30-CA077598)
This publication has 99 references indexed in Scilit:
- Agonism and Antagonism at the Insulin ReceptorPLOS ONE, 2012
- Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer TreatmentCancer Research, 2012
- Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancerCancer, 2011
- Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studiesThe Lancet Oncology, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Biological effects of growth hormone on carbohydrate and lipid metabolismGrowth Hormone & IGF Research, 2010
- Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal CancerJournal of Clinical Oncology, 2009
- Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1Oncogene, 2007
- The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificityProceedings of the National Academy of Sciences, 2006
- Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysisThe Lancet, 2004